Do eosinophil-targeting biologics affect COVID-19 patients?
There is no evidence for an enhanced susceptibility of patients on anti-IL-5/IL-5R treatment to develop viral infections. Observational studies in COVID-19 patients reported elevated eosinophil counts with a favorable outcome, whereas eosinopenia was observed in more severe cases.22,57 Neither was there proof of causation nor evidence for enhanced tissue presence in lungs of COVID-19 patients.58